NCT05239624 2026-04-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT07221942 2026-02-19
IMPROEV
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05868265 2026-02-17
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT06356155 2025-07-29
NEPTUNE
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT03606174 2023-08-24
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Phase 2 Terminated